TAK-007

BIOLOGICAL2 trials

Sponsors

Takeda

Conditions

Refractory Lupus NephritisRefractory Systemic SclerosisRelapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 1

A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

WithdrawnNCT06377228

TakedaRefractory Lupus Nephritis, Refractory Systemic Sclerosis

Start: 2025-06-13End: 2030-09-02Updated: 2025-04-06

Phase 2

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Active, not recruitingNCT05020015

TakedaRelapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Start: 2021-11-12End: 2038-12-20Updated: 2026-03-31

Related Papers

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Blood2024-11-053 citations